• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Novel antiviral tetrahydroimidazo[1,4]benzodiazepin-2-ones of formula <CHEM> a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof, wherein R<1> is hydrogen, C1-8alkyl, C3-6alkenyl, C3-6alkynyl, C1-6alkylcarbonyl, C3-6cycloalkyl, or substituted C1-6alkyl; R<2> is hydrogen, C1-6alkyl or C3-6alkenyl R<3> is hydrogen or C1-6alkyl; R<4> is hydrogen; substituted C1-6alkyl; C1-6alkylcarbonyl; C3-6alkenyl; C3-6cycloalkyl; C5-6cycloalkenyl; R<5> is hydrogen, C1-6alkyl or halo; and aryl is optionally substituted phenyl; pharmaceutical compositions containing these compounds as active ingredient; processes for preparing said compounds and compositions.
    公开号:SU1748647A3
    申请号:SU894613664
    申请日:1989-03-17
    公开日:1992-07-15
    发明作者:Херман Маргарета Реймакерс Альфонс；Людовикус Хубертус Ван Гелдер Йозефус；Джозеф Кукла Майкл；Джозеф Бреслин Генри；Адриан Ян Жанссен Поль
    申请人:Жансен Фармасетика Н.В. (Фирма)；
    IPC主号:
    专利说明:

    VN-f R,
    The invention relates to a process for the preparation of new tetrahydroimidazo (1,4) benzodiazepin-2-ones of the general formula
    V
    or their addition salts with pharmaceutically acceptable acids, or stereochemically isomeric forms, where RI is Cf-Sv-alkyl; Sz-Ce-alkenide; Sz-Ce-alkynyl; Ci-Ce-alkyl; substituted by phenyl or C3 Ce-cycloalkyl;
    R2 is hydrogen or methyl;
    Bs - hydrogen or methyl;
    R4 is hydrogen or hydroxymethyl, possessing antiviral activity,
    4,9-dibromo-6- (4-methyl-1-pi-pye razinyl) benzo b-pyrrolo 3,2,1-j, (1,4) benzodiazepine, also exhibiting antiviral activity is known .
    The purpose of the invention is to obtain new 1,4-benzodiazepine derivatives with greater activity and low toxicity.
    The goal has been achieved by a process for the preparation of compounds of general formula (I), which consists in the fact that 9-amino-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine of general formula
    T.L.
    where Ri, RZ, Ra and R4 have the indicated meanings,
    condense with a carbonyl releasing reagent of formula
    Z-C (0) -Z
    where Z is an easily cleavable group, if necessary in a reaction-inert solvent and in the presence of a base and, if necessary, the target product obtained
    V4-f R3
    - -R2
    -N
    Hsn2-c6n5
    wherein R2, RS, and R4 are as defined, hydrogenated in a reaction inert solvent in the presence of a metal catalyst and under hydrogen atmosphere to give a compound of the general formula O
    followed by N-alkylation with a reagent of the formula
    0
    Ri - W (IV)
    where W is a reactive leaving group;
    RI - has the indicated values, in a reaction-inert solvent in the presence of a base and, if necessary, an iodide salt, to give the desired compound of the general formula O
     R3
    to-
    Chg
    one
    or if necessary, subjected to N-alkylation of the target product of General formula Q
    HN-
    N5
    where R4 is hydrogen;
    Ri, R2 and RS are as indicated, using formaldehyde to form the desired product of formula Q
    HO-CHjTN-f R
    M-VR2 N

    where Ri, R2 and R3 are as defined,
    followed by isolating the desired product in the free state or converting it to a therapeutically active non-toxic acid addition salt by treating the compounds of formula (I) with an acid and / or get stereochemically isomeric forms of the desired product.
    Obtaining intermediate compounds. PRI me R 1.
    A solution of 2.6 g of methyl 2: bromo-3-nitrobenzozoate, 1.75 g of M- (2-amino-1-methyl) zolmethanamine and 1.06 g of sodium carbonate in
    8 g of 1-butanol is stirred and refluxed for 30 minutes. The solvent is evaporated. 20 g of water are added to the residue. The product is extracted twice with 30 g of trichloromethane. United
    the electrodes are dried, filtered and evaporated. From the oily free base, the hydrochloride salt is prepared in a known manner. The salt is separated by filtration, washed with 2-propanol and dried.
    3.4 (89.5%) methyl 3-nitro-2- (2-methyl-2 - {{phenylmethyl) mino-ethyl amino / benzoate hydrochloride is obtained, m.p. 204 ° C (intermediate 1).
    A mixture of intermediate 1 in the amount of 3.8 g, 15 g 2n. hydrate solution
    sodium oxide and 4 g of 2-propane-1ol are mixed and refluxed for 1 hour. A solution of 3 g of concentrated hydrochloric acid and 5 g of water is added to the boiling reaction mixture. After cooling, the product is precipitated, separated by filtration, washed with water and subjected to recrystallization from 80 g of glacial acetic acid.
    3 g (82%) of 3-nitro-2 - (/ {{(nylmethyl) amino 3-2-methyl} ethyl / amino) benzoic acid are obtained, m.p. 227 ° C (intermediate compound 2),
    The mixture of intermediate 2 in the amount of 189.3 g, 400 g of thionyl chloride and 400 g of methylbenzene is stirred and refluxed for 2 hours. The solvent is evaporated and the residue is taken up in 600 g of methylbenzene. The solution is treated with an acidic sodium carbonate solution. The separated organic layer is dried over anhydrous carbonate. filter and concentrate to a volume of about 500 ml. After being kept at room temperature, the product is partially precipitated. It is separated by filtration (the filtrate is separated), washed successively with 2-propanol and 1,1-oxybisethane and dried, resulting in a first fraction from 123.5 g of crude 2,3,4,5-tetrahydro-3- methyl-9-nitro-4- (phenylmethyl) -1H-1,4-benzodoazepin-5-one. From the mother liquor, the solvent is evaporated. The residue is dissolved in 160 ml of boiling 2-propanol and crystallized at room temperature. The precipitated product is filtered, washed successively with 2-propanol and 1,1-oxybisethane and dried, resulting in a second less pure fraction of 28 g of 2,3,4,5-tetrahydro-3-methyl-9-nitro-4- (hair dryer Il-methyl) -1 H-1,4-benzodiazepin-5-one. Both crude fractions are recrystallized from ethanol
    Obtain 137 g (85%) 2,3,4,5-tetrahydro-3-methyl-9-nitro-4- (phenylmethyl) 1 H-1,4-benzodiazepin-5-one, mp 125 ° C (intermediate 3)
    To a stirred and refluxed suspension of 14 g of aluminum lithium hydride in 40 g of benzene and 50 g of tetrahydrofuran, a solution of 20.2 g of intermediate 3 in 200 g of tetrahydrofuran is added, stirred and refluxed for 2.5 hours. The reaction mixture is cooled in crushed ice and separated by successive additions of water, 15% sodium hydroxide solution and again water. The inorganic material is separated by filtration, the filtrate
    evaporated. 40 g of methylbenzene are added to the residue, this solution is evaporated to dryness.
    19.8 g (87.6%) of 9-amino-2,3,4,5- 5 tetrahydro-3-methyl-4- (phenylmethyl) -1H-1,4-benzodiazepin-5-one are obtained in the form red oily residue, which is used without further purification (intermediate 4).
    0 Example2
    To a stirred and cooled f-12 ° C) mixture of 9.10 g of 2-amino-3-nitrobenzoic acid, 6.95 g of methyl (1) -2-aminopropanoate hydrochloride, 13.50 g of hydrate and 1-hydroxy-1H -benzotriazole and 180 g of tetrahydrofuran were added 5.05 g of 4-methylmorpholine in an argon atmosphere. After stirring for 5 minutes, 1030 g of M, M-methane tetrayl 0 bis cyclohexanamine was added to the mixture.
    allowed to warm to room
    temperature and stirred for another 16 h
     The mixture is cooled for 30 minutes to 0 ° C
    and then filtered. The filtrate is concentrated under reduced pressure, and the residue is divided between 225 g of ethyl acetate and 250 g of a saturated solution of sodium hydrogencarbonate. The separated organic layer is washed with 100 parts of a saturated solution.
    0 sodium hydrogen carbonate, dried, filtered and concentrated under vacuum
    13.08 g (97.9% of (-) - methyl- (5) -2- (2-amino-3-nitrobenzoyl) amino propanoate) are obtained, mp 132.9 ° C (Intermediate 5)
    5 A mixture of 12.58 g of intermediate 5 and 160 g of ethanol is subjected to hydrogenation in a Parr apparatus at a pressure of 3–10 Pa and room temperature with 3.50 g of palladium on charcoal as a catalyst (10%) for 4 hours. are filtered on diatomaceous earth and the filtrate is concentrated under reduced pressure. The oily residue is placed in an oil bath at 150 ° C at
    5 pressure 3.3-310 Pa. The temperature is maintained at 200 ° C for 40 minutes with stirring. After cooling, the precipitated product is separated and triturated with 12 g of ethanol. The product is separated by filtration, washed with a small amount
     cold ethanol and 1,1-oxybisethane and dried, resulting in a gain of 5.58 g
    (57.7%) (+) - (5) -9-amino-2,3-dihydro-3-methyl, 1H-1,4-benzodiazepin-2.5- (4H) -dione (intermediate 5 )
    Froze
    In a stirred solution of 11.32 g N, N metantetrailbis (cyclohexanamine) in 45 g
    tetrahydrofuran is added with a solution of 10 g of 2-amino-3-nitrobenzoic acid and 7D2 g of 1-hydroxy-1H-benzotriazole hydrate in 180 g of tetrahydrofuran, and then a solution of 5.5 g of 4-methylmorpholine in 45 g of tetrahydrofuran B, thus obtained the mixture is added with a solution of 6 g of 1-amino-2-propanone hydrochloride in 47 g of NN-dimethylformamide, stirred for 22 hours under nitrogen atmosphere. An additional 1.5 g of 1-amino-2-propanone hydrochloride and 1,4-h.4-methylmorpholine are added. The same amount of these products is added after stirring for 24 hours. After a total reaction time of 3 days is reached, the reaction mixture is filtered and the filtrate is concentrated. The residue was dissolved in dichloromethane, and the organic layer was washed successively twice with water, a saturated solution of sodium hydrogencarbonate and sodium chloride solution, dried, filtered and evaporated. The residue is subjected to crystallization from ethanol.
    8.34 g (63.9%) of 2-amino-3-nmt-po-N (2-oxopropyl) -benzamide are obtained (intermediate compound 7)
    A mixture of 7.2 g of intermediate 7 and 120 g of ethanol is hydrogenated in a Parr apparatus at a pressure of 3.5-105 Pa with 1.7 g of 10% palladium on charcoal as a catalyst. After absorbing the calculated amount of hydrogen, the catalyst is separated by filtration on diatomaceous earth, washed with dichloromethane, and the filtrate is concentrated.
    5.5 g (96.9%) of 9-amino-3,4-di-hydro-2-methyl-5H-1,4-benzodiazepin-5-one are obtained (intermediate compound 8).
    Preparation of the final compounds. EXAMPLE 4 A mixture of 19.8 g of intermediate 4 and 7.2 g of urea is heated to 210-220 ° C until foaming and cessation of evolution of gaseous ammonia (approximately 10 minutes), the reaction mixture is cooled to approximately 100 ° C and boiled with 120 g of 1N hydrochloric acid solution. The solution is decanted from the oily residue, treated with activated charcoal and filtered. The filtrate is cooled and alkalinized with ammonium hydroxide. The product is extracted once with 75 g of trichloromethane and once with 150 g of trichloromethane. The combined extracts are dried and evaporated. The residue is triturated in 24 g of 2-propanol, filtered and recrystallized from ethanol, and then from 4-methyl-2-pentanone.
    2.5 g (11.5%) of 4,5,6,7-tetrahydro-5-methyl-6- (phenylmethyl) imidazo-4,5,1- (1,4) - benzodiazepin-2 ( 1 H) -one, t PL 205 ° C (compound 1)
    PRI me R 5 Mixture of Compound 1 in
    the amount of 8 g, 1 g of 10% palladium on charcoal as a catalyst in 80 g of glacial acetic acid is subjected to hydrogenation at a temperature of about 38 ° C. After the calculated amount of hydrogen was taken up, the catalyst was separated by filtration, and the acetic acid was evaporated. The residue is dissolved in 75 g of water, the solution
    The mixture is basified with 30 g of a concentrated solution of ammonium hydroxide. The product is crystallized at room temperature, separated by filtration, washed with water and recrystallized from 20 g of 2-propanol.
    3.7 g (66.8%) of 4,5,6,7-tetrahydro-5-methylimidazo 4,5, (1,4) -benzodiazepi-n-2 (1H) -one are obtained, m.p. 190.5 ° C (compound 2). PRI me R 6 At 25 ° C in a stream of argon
    0 5.0 g of intermediate 6 is added to a suspension of 5.55 g of lithium aluminum hydrate in 154.5 g of 1,4-dioxane. The reaction mixture is refluxed for 5 hours. After cooling to 10 ° C, 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 Bavl water, 5 to 15 g of sodium hydroxide solution and 16.65 water,
    stirred for 2 h and then filtered.
    The precipitate is washed successively with 178 g
    hot tetrahydrofuran and 133 g dichloro methane. The combined filtrates are dried, filtered and evaporated. The residue is poured into a solution of 7.36 g of thiomorpholine in 133 g of dichloromethane. The mixture is added to a solution of 4.82 g of trichloromethyl chloroformate in 160 g of methylene dichloride for 15 minutes at a temperature of 0 ° C and in a stream of argon. After stirring for 10 minutes at 0 ° C, the reaction mixture is warmed to room temperature and concentrated by evaporation. 70 g of an aqueous solution of 1,4-dioxane (15%) are added to the residue and the mixture is heated in a steam bath under a stream of nitrogen for 45 minutes, cooled and extracted with dichloromethane (2 x 66.5 g). The aqueous layer is filtered and
    5 is alkalinized with concentrated ammonium hydroxide. The precipitate is separated by filtration, washed with a small amount of cold water, dried and triturated twice with 6.24 g of 2-propanol,
    0 1.59 g (32.1%) of (+) - (S) -4,5,6,7-tetrahydro-5-methylimidazo 4,5, (1,4) b-enzodiazepine-2 (1 H ) -one, t PL 206.5 ° C (compound 3).
    Example. Compound 2 solution in
    5 amounts of 6, 5, 4.65 g of 3-bromo-2-propene, 3.85 g of N. N-diethylethanamine and several potassium iodide crystals in 80 g of 1-butanol are stirred and refluxed for 15 hours. The solvent is evaporated. 100 ml of water are added to the residue and the product
    extracted twice with trichloromethane. The combined extracts are dried and evaporated. The residue is triturated in 160 g of hot 2, sibispropane, boiled with activated charcoal, filtered, and the filtrate is concentrated. The product is purified through an oxalate salt in a known manner, in which case a free base is obtained. The latter is first crystallized from 20 g of 2,2-oxy-bis-propane, and then from 12 g of 2-propanol. 2.5 g (32.1%) of 4,5,6,7-tetrahydro-5-methyl-6- (2-lropenyl) -imidazo 4,5, (1,4) benzodiazepine-1 (C-) are obtained. ) -one, so pl. 138 ° C (compound 4).
    Try on To a stirred solution of Compound 2 in the amount of 1.0 g, 0.816 g of potassium iodide and 0.782 g of sodium carbonate in 56.4 g of M, M-dimethylformamide, a solution of 0.88 g of 4-bromo-2-methyl-1- is added dropwise. butene in 14 g of M, M-dimethylformamide. After stirring for 22.5 hours at room temperature, the reaction mixture is concentrated under vacuum at 70 ° C. The residue is distributed twice between 130 g of dichloromethane and 100 g of a mixture of water and a saturated aqueous solution of sodium hydrogencarbonate (50:50 by volume). The combined aqueous layers were extracted with 78 g of dichloromethane. The dichloromethane layers were combined and extracted with 100 g of a saturated solution of sodium chloride. This extract is dried, filtered and concentrated under vacuum at 40 ° C. The residue is crystallized twice from 16 g of acetonitrile, cooled 45 minutes to 0-5 ° C. The crystallized product is separated by filtration, washed with 4 g of cold (0-5 ° C) acetonitrile and dried overnight under vacuum at 78 ° C.
    0.805 g (60.3%) of (+) - 4.5.6,7-tetrahydro-5-methyl-6- (3-methyl-2-butenyl) im-, 5.1- (1.4) are obtained. -Benzodiazepin-2 (1 H) - it, so pl. 158.0 ° C (compound 5).
    PRI me R, 9. In a stirred and cooled (0 ° C) solution of compound 2 in
    An amount of 1 g, 1.33 g of 1-hydroxy-1H-benzotriazole and 23.5 g of M, M-dimethylformamide was added 0.29 g of glacial acetic acid in a stream of argon. After stirring for 5 minutes at 0 ° C, 1.02 g of N.N-methane-Rabis (cyclohexanamine) is added. Stirring is continued for 1.5 hours at 0 ° C and for 2 days at room temperature. The reaction mixture is cooled to 0 ° C for 1 h, and then filtered. The filtrate is concentrated by evaporation, and the residue is transferred to a saturated solution of sodium hydrogencarbonate. The product is extracted with dichloromethane and the extract is washed successively with aqueous 2N. citric acid solution and a saturated solution of acid carbonate
    sodium, dried, filtered and evaporated. The residue is purified using a chromatographic column (silica gel; dichloromethane-methanol 97.5: 2.5). The eluent fraction was evaporated and the residue was crystallized from methanol. The product is dried overnight under vacuum at 82 ° C.
    0.48 g (39.9%) of 6-acetyl-4,5,6,7-tetrahydro-5-methyl-imidazo 4,5, (1,4) 0 benzodiazepin-2 (1H) -one is obtained, m.p. . 249.3 ° C (compound 6).
    An example.
    A mixture of 4.2 g of 4,5,6,7-tetrahydro-b- (phenylmethyl) -imidazo 4,5, (1,4 benzodiazine pin-2 (1H) -one of monochloride (compound 7), 10 h. Acetic anhydride and 10 g of glacial acetic acid are stirred and refluxed for 4 hours. The solvent is evaporated. The residue is added
    0 ammonium hydroxide solution, while cooling simultaneously in an ice bath, and the product is extracted three times .75 g of trichloromethane. The combined extracts are dried, filtered and evaporated. Solid residue shake
    5 in 40 g of methanol, filtered again and recrystallized three times from 20 g of 2-methoxyethanol.
    Obtain 2.5 g of 1-acetyl - & - (phenylmethyl) - 4,5,6,7-tetrahydroimidazo 4,5, (1,4J0 benzodiazepin-2 (1H) -one, so pl. 168-173 ° C ( connection 8).
    PRI me R 11. A mixture of 5.6 g of 4,5,6,7-tetrahydro monochloride: -6- (phenylmethyl) -imidaz-, 5, (1,4) - benzodiazepin-2 (1 H) - she is
    5 (compound 7), 1.05 g of a 50% sodium hydride dispersion in 64 g of methylbenzene is stirred until the evolution of hydrogen ceases. Then it is stirred at reflux for 30 minutes. The methyl benzene layer is evaporated. A solution of 3.4 g of methyl iodide in 40 g of M, M-dimethylformamide is added to the residue. All this is stirred for 1 h without heating, and then 15 minutes at 50 ° C, n, M-dimethylformamide is evaporated.
    5 50 ml of water were added to the residue and the product was extracted twice with 75 g of trichloromethane. The combined extracts are dried, filtered and evaporated. The residue is dissolved in 30 g of hydrochloric acid solution and 30 g
    0 water. This solution is washed with 50 g of digroin and treated with activated charcoal. The solution is alkalinized with ammonium hydroxide and the product is extracted twice with 40 gmethylbenzene. The combined extracts are dried, filtered and evaporated. An oxalate salt is obtained from the oily free base in a known manner. The crude salt is separated by filtration, recrystallized from methanol and dried.
    2.7 g of oxaleth 6-benzyl-4,5,6,7-tetrahydro-1-methylimidazo 4,5,1- (1,4) -benzodiazepin-2 (1H) -one are obtained, m.p. 200-202.5 ° C (compound 9).
    For example, 12. A mixture of 4 g 4,5,6,7-tetrahydro-6- (2-phenylethyl) -imidazo-4,5,1-jkHl, 4) -benzodiazepin-2 (1H) -one (compound 10), 10 g of a 40% formaldehyde solution in water and 40 g of 2-propanol are stirred and refluxed for 16 hours. The solvent is evaporated. 20 g of 4-methyl-2-pentanone is added to the residue and the latter is evaporated again. The residue is dissolved in 40 g of 2-propanol. An excess of 2-propanol saturated with gaseous hydrogen chloride is added to the solution. The precipitated product is separated by filtration, dried and recrystallized from 25 g of water.
    3.7 g of hydrochloride 4,5,6,7-tetrahydro-1- (hydroxymethyl) -6- (2-phenylethyl) -imidazo 4,5, (1,4) -benzodiazepin-2 (1) are obtained. H) - it is, mp, 217.5 ° C (compound 11).
    In tab. 1 shows the physical data of the compounds obtained.
    The compounds of formula (I) possess antiviral and, in particular, anti-viral activity.
    The antiviral, in particular anti-retroviral, and especially the anti-CVI properties of the compounds of formula (I) allow them to be used as antiviral chemotherapeutic agents for the prevention or treatment of warm-blooded animals suffering from viral infection.
    Antiretroviral activity and cytotoxicity of the compounds of formula (I) can be determined using the in vitro anti- (PNI) -analytic system, the 50% antiviral effective dose (EDB), / and g / ml) is determined using an analysis of the cytopathic effect ( CPD), which is based on cell viability, as determined by the trypan blue exclusion procedure. The 50% cytotoxic dose (CDso, / Lg / ml) is analyzed by falsely infecting MT-4 cells. For the proposed compounds, CDso was found to vary in the range from 165 to 250 / g g / ml, -a EDso from 8 to 22 c g / ml. Neither atactic nor sedative effects were detected.
    Treatment of viral diseases in warm-blooded animals suffering from viral diseases, possibly through the use of an effective antiviral amount of a compound of formula (I), which is acceptable from a pharmaceutical point of view, an acid addition salt or a stereoisomeric form. The effective amount varies from 0.1 to 200 mg / kg body weight, in particular from 1 to 50 mg / kg body weight.
    It is preferable to apply the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Subdoses may be presented in the form of unit doses, for example, containing from 1 to 1000 mg, in particular from 5 to 200 mg, of the active ingredient per unit dose form.
    The known compound with 4,9-dibrom-6- (4-methyl-1-piperazinyl) -benzo (c) -pyrrolo,
    3.2, (1,4) -benzodiazepine (HP-370), does not possess the antiviral properties that the proposed compounds demonstrate, the effective dose (EDso) of the known compound is higher than the cytotoxic dose (CDso),
    te compound kills cells before it starts to heal them
    The relative safety of the proposed compounds is established by the ratio of the cytotoxic dose to the effective,
    those. by selectivity index:
    SI CDgo / EDso.
    Comparative biological data. The SI selectivity index indicates the relative efficacy of the proposed compounds as an antiretroviral drug (see, Table 2).
    权利要求:
    Claims (1)
    [1]
    Thus, the proposed compounds have a pronounced retroviral activity and lower toxicity than the known structural analogue. Invention Method for producing tetrahydroimidazo (1,4) -benzodiazepin-2-ones of the general formula
    (ABOUT
    about
    where RI is Ci-C3-alkyl, C3-Ce-alkenyl Ct-Ce-alkynyl, Ci-Cb-alkyl substituted by phenyl or Cs Cb-cycloalkyl;
    R2 is hydrogen or methyl;
    Рз - hydrogen or methyl;
     - hydrogen or hydroxymethyl, or their salts of addition of pharmaceutically acceptable acids, or their stereochemically isomeric forms, characterized in that 9-amino-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine of the general formula
    R4-NHH l
    where RI, R2, Ra and R4 have the indicated meanings,
    condense with a carbonyl releasing reagent of formula
    Z-C (0) -Z where Z is an easily cleavable group, if necessary in a reaction-inert solvent and in the presence of a base and, if necessary, the obtained target product of the general formula
    CH2-C6H5 where R2, RS and RA have the indicated meanings, is subjected to hydrogenation in a reaction-inert solvent in the presence of a metal catalyst and in an atmosphere of hydrogen to obtain a compound of the general formula
    followed by N-alkylation with a reagent of the formula
    R1-W, where W is a reactive leaving group,
    ten
    (CHJ, CfiH
    g gp510
    15
    0
    five
    0
    five
    RI has the indicated meanings in a reaction-inert solvent in the presence of a base and, if necessary, an iodide salt to give the desired compound of the general formula
    R TN - f D
     3 kX VR
     V I N-vp K1
    or, if necessary, subjected to N-alkylation of the target product of the general formula O
    HN-f R
    r v-N-f J
    SC ".
    4Ri
    where R-i is hydrogen;
    RI, Ra and Ra are as indicated, using formaldehyde to give the desired product of the general formula
    no-cng-n-y ° r (
    --N g
    where RI, R2 and Ra are as defined,
    followed by isolating the desired product in the free state, or converting it to a therapeutically active non-toxic acid addition salt by treating the compound of general formula (I) with an acid and / or get stereochemically isomeric forms of the desired product.
    o6
    200-202.5 ° C t „area 1b5,5 ° C,
    Continuation of table 1
    17
    1748647
    18 Table 2
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1748647A3|1992-07-15|Method for synthesis of tetrahydroimidazo-|- benzodiazepine-12-onъs or theirs joining salts or pharmaceutically acceptable acids or theirs stereochemically isomeric forms
    JP2009510004A|2009-03-12|Pyrazolo [1,5-α] pyrimidinyl derivatives useful as corticotropin releasing factor | receptor antagonists
    KR20170123607A|2017-11-08|Cell Necrosis Inhibitors and Related Methods
    WO1998014451A1|1998-04-09|Fused pyrazole derivative and process for its preparation
    PL213669B1|2013-04-30|Derivative of 2-oxo-1-pyrrolidyne, pharmaceutical agent and the use of this derivative
    CA2561639A1|2005-10-06|Novel urea derivatives and their medical use
    CA2611607A1|2007-01-18|Indolylmaleimide derivatives
    EP0063381A1|1982-10-27|Pyrazolo| pyrimidines, process for their preparation and pharmaceutical compositions containing them
    US4985434A|1991-01-15|7-substituted derivatives of 2-amino-3H,5H-pyrrolo|pyrimidin-4-ones and pharamceutical uses and compositions containing the same
    JP2009539936A|2009-11-19|Pyrazolopyrimidone
    ES2241752T3|2005-11-01|DERIVATIVES OF AZABICICLOALCANS TO USE AS INHIBITORS OF THE RECOVERY OF SEROTONINE AND ANTAGONISTS OF 5HT2A.
    CA3081751A1|2019-05-09|Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
    US5008265A|1991-04-16|2-amino-7-|-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
    NZ237363A|1992-12-23|Imidazo|quinazoline derivatives, preparation and pharmaceutical compositions thereof
    CZ39594A3|1994-11-16|Derivative of isatinoxime, process of its preparation and pharmaceutical preparation in which it is comprised
    US5677306A|1997-10-14|Derivatives of 5H, 10H-imidazo 1, 2-a!indeno 1,2-e!pyrazin-4-one, preparation thereof and medicaments containing them
    JP3010558B2|2000-02-21|Novel 1,7-fused 1H-indole-2-carboxylic acid-N- | -amides, their preparation and cholecystokinin antagonists containing the same
    US4985433A|1991-01-15|2-amino-7-|-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
    US5852190A|1998-12-22|Diazepinoindoles as phosphodiesterase IV inhibitors
    EP1320528A2|2003-06-25|Substituted phthalides as anti-convulsive drugs
    WO1990010631A1|1990-09-20|9-substituted-8-unsubstituted-9-deazaguanines
    DE69922936T2|2005-12-08|USE OF INDOL-2,3-DIONE-3-OXIM DERIVATIVES AS AMPA ANTAGONISTS
    PL182747B1|2002-02-28|Derivatives of morphine having condensed heterocyclic ring
    DE2150062A1|1973-04-12|Imidazo|pyrido|pyrimidines - withcns activity
    AU732214B2|2001-04-12|Biphenyl derivatives and drug composition
    同族专利:
    公开号 | 公开日
    DE68904102T2|1993-05-06|
    NO891176L|1989-09-19|
    KR0133073B1|1998-04-17|
    GR3006728T3|1993-06-30|
    IE63108B1|1995-03-22|
    HU206873B|1993-01-28|
    DE68904102D1|1993-02-11|
    IE890851L|1989-09-18|
    NZ228216A|1991-01-29|
    HUT52099A|1990-06-28|
    HU203757B|1991-09-30|
    JO1589B1|1989-12-16|
    BG51251A3|1993-03-15|
    NO891176D0|1989-03-17|
    FI891279A|1989-09-19|
    JP2693559B2|1997-12-24|
    IL89633D0|1989-09-28|
    NO167737C|1991-12-04|
    TNSN89039A1|1991-02-04|
    FI89800C|1993-11-25|
    PT90034A|1989-11-10|
    FI891279A0|1989-03-17|
    ES2053946T3|1994-08-01|
    FI89800B|1993-08-13|
    MY104942A|1994-07-30|
    IL89633A|1994-02-27|
    AU8360291A|1991-11-07|
    JPH01275582A|1989-11-06|
    DK130989D0|1989-03-17|
    AU630575B2|1992-10-29|
    AT84035T|1993-01-15|
    CN1031058C|1996-02-21|
    ZA892062B|1990-11-28|
    KR890014546A|1989-10-24|
    PH27044A|1993-02-01|
    CA1310964C|1992-12-01|
    HU911782D0|1991-12-30|
    AU3131089A|1989-09-21|
    AU617435B2|1991-11-28|
    EP0336466A1|1989-10-11|
    PT90034B|1994-05-31|
    CN1036957A|1989-11-08|
    GB8806449D0|1988-04-20|
    NO167737B|1991-08-26|
    DK130989A|1989-09-19|
    EP0336466B1|1992-12-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US10370378B2|2007-08-20|2019-08-06|Evotec International Gmbh|Treatment of sleep disorders|FR2534257B1|1982-10-12|1984-12-28|Roussel Uclaf|
    IL93136A|1989-02-23|1995-01-24|Janssen Pharmaceutica Nv|Tetrahydroimidazo benzodiazepin-2-thione derivatives, their preparation and pharmaceutical compositions containing them|IL93136A|1989-02-23|1995-01-24|Janssen Pharmaceutica Nv|Tetrahydroimidazobenzodiazepin-2-thione derivatives, their preparation and pharmaceutical compositions containing them|
    US5270464A|1989-03-14|1993-12-14|Janssen Pharmaceutica N.V.|Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2- ones|
    NZ235137A|1989-09-13|1992-02-25|Janssen Pharmaceutica Nv|Tetrahydroimidazobenzodiazepine derivatives, preparation and pharmaceutical compositions thereof|
    US5164376A|1989-10-30|1992-11-17|Hoffmann-Laroche Inc.|Method for treating retroviral infections with aryl- keytone compound|
    EP0436245A1|1989-12-27|1991-07-10|Duphar International Research B.V|Substituted 3,4-annelated benzimidazol-2-ones|
    US5141735A|1990-06-18|1992-08-25|Hoffman-La Roche, Inc.|Substituted amino-benzodiazepines having anitviral activity|
    NZ238664A|1990-07-06|1992-12-23|Janssen Pharmaceutica Nv|Substituted tetrahydroimidazobenzodiazepin-2-ones and pharmaceutical anti-viral compositions|
    GB9018601D0|1990-08-24|1990-10-10|Fujisawa Pharmaceutical Co|Tricyclic compounds|
    DE4036552C1|1990-11-16|1992-02-06|Boehringer Mannheim Gmbh, 6800 Mannheim, De|
    GB9109557D0|1991-05-02|1991-06-26|Wellcome Found|Chemical compounds|
    DK0639971T3|1992-05-13|2000-03-20|Wellcome Found|Therapeutic combinations|
    US6177435B1|1992-05-13|2001-01-23|Glaxo Wellcome Inc.|Therapeutic combinations|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB888806449A|GB8806449D0|1988-03-18|1988-03-18|Antiviral hexahydroimiazobenzodiazepin-2-ones|
    [返回顶部]